Friday, 18 May 2012
LEGAL NOTICE
CONTACT US
SITEMAP
HOME
PRODUCTS
Product selection guide
Human Cardiomyocytes iPS
Cor.4U MEA
Murine Cardiomyocytes ES
CELLS
Cor.At GFP
Cor.At CL - Colorless
CUSTOMIZED FORMATS
Cor.At-X xCELLigence Cardio
KITS
Cor.At GFP Starter Kit
Cor.At RNA (Day 2 & Day 14)
Cor.At Cardiotoxicity Kit
Murine Cardiomyocytes iPS
Cor.At Colorless iPS
Murine Endothelial Cells
Endo.4M
Murine Smooth Muscle Cells
Smac.4M
SERVICES
Services selection guide
Electrophysiology Services
Human MEA (Cor.4U)
Mel.Cor MEA (Cor.At)
Cor.At CardioEffect Screening
Toxicology Services
µEST - Embryotoxicity
Cor.At Tox
E-Screen
ToxEffect screening
General cytotoxicity testing
Drug Development Services
My.Cor - Cardiomyopathy screen
Customized Services
APPLICATIONS
Application selection guide
Electrophysiology
Manual patch clamp
Automated patch clamp
MEA analysis
Calcium flux analysis/Fluo-4 FLIPR
Roche xCELLigence Cardio
Roche xCELLigence Cardio with Cor.At
Cardiotoxicity
Neutral Red Uptake
Troponin release
Label-free analysis
Mitochondrial toxicity
Oxygen consumption (MitoXpress®)
Drug profiling & target discovery
Hypertrophy
Gene expression
Transfection
SCIENCE & TECHNOLOGY
Stem cell technology
Embryonic stem cells
Induced pluripotent stem cells
Product technology
Drug discovery
Documentation
Publications
COMPANY
Meet us
News & Media
Overview / Profile
Management & Team
Executive Board
Statements
Advisory Board
Scientific Advisory Board
Investor Relations
Partners
Contact us
Login
Axiogenesis and Yamanaka (iPS Academia) sign
license agreement to generate
(iPS) derived HUMAN CARDIOMYOCYTES and other tissue
Important patent granted to
Axiogenesis
i
n Europe and Japan
on the use of hypertrophic cardiac cells in drug development
Meet us
News & Media
Overview / Profile
Management & Team
Executive Board
Statements
Advisory Board
Scientific Advisory Board
Investor Relations
Partners
Contact us
Login
Statements Executives
